Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. Enveric is committed to developing novel treatments to transform the lives of patients living with mental illness. We are pursuing new pathways and targeting impaired neural circuitry with the goal of improving brain health. Our mission is to pioneer new and innovative solutions with the potential to have profound effects on patients and their families, and to deliver life-changing medicines for diseases affecting the brain. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada.